RE:RE:RE:RE:Nothingqwerty22 wrote: PinnacleX wrote: SPCEO1 wrote: Last year on the VM news, we had around 2 million shares trade pre-market and the stock was up 50%. This year, the research showed a melonoma tumor was vanquished in 21 days but the robot traders were apparently not plugged in this morning so we traded up a few pennies on 12,000 shares in the pre-market.
What a bizarre stock!
So far, none of the analysts have commented on the AACR news (Canaccord put out a perfunctory blurb when they announced the abstracts were available back in March).
It sure seems like the only people investors attention to TH are the people who are part of this message board. And we already own the stock in a substantial way, largely after doing the homework to convince ourselves of its value by ourself. So, yes, we have a IR problem as has been pointed out endlessly, but with no apparent action being taken to remedy the sad state of affairs as best we can see.
longterm56 wrote: A big yawn in pre-market trading. Another great achievement by the IR people. Not just anytime can keep the share price smothered after such great news. Truly amazing.
Bizarre is an understatment, its unheard of. This should be double on that news alone, WTF a tumor gone using your treatment in 21 days!!!! and NOTHING! what makes it even more so its on the NYSE and it doesnt get picked up there aswell.
Nope, the oddest thing was the 50% rise last year. This years AACR data is not worth $450 million.
Not yet, but it might be on the way to being worth much more than that. It was encouraging to see the details in the poster - it gave me additional confidence that they may actually have something that will work out in cancer. I am sure there will be many more twists and turns ahead as the trial proceeds but there could be a pot of gold at the end of the TH-1902 rainbow and the chances that is the case just got nudged a little higher.